Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 5;217(2):635–647. doi: 10.1083/jcb.201606095

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Gong et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 6. — Effect of in vivo treatment with HNG on hepatic CMA. (A–D) CMA activity in the liver from rats treated with 2 mg/kg of HNG or SP for 6 h. Immunoblots for LAMP-2A (A and C) and GAPDH (A) or RNase A (C) in lysosomes isolated from livers of untreated (control; Ctr) or HNG-treated rats and incubated with the two different substrates. Quantification of the binding (B and D) and uptake (B) of the substrates in n = 4 (B) or n = 2 (D) animals. (E) Immunoblots for the indicated proteins in CMA-active lysosomes isolated from the same animals as in A. Bottom shows quantification of the levels of the indicated proteins in HNG-treated animals relative to those in control untreated. n = 4. All values are means + SEM. Differences with untreated animals were significant for *, P < 0.05.